Structural Variants as a Basis for Targeted Therapies in Hematological Malignancies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Frontiers in Oncology 9 (2019) 839, 1-7
- Ereignis
-
Veröffentlichung
- (wo)
-
Münster
- (wer)
-
Universitäts- und Landesbibliothek Münster
- (wann)
-
2020
- Urheber
- DOI
-
10.3389/fonc.2019.00839
- URN
-
urn:nbn:de:hbz:6-59029480356
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:34 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Schütte, Judith
- Reusch, Julia
- Khandanpour, Cyrus
- Eisfeld, Christine
- Universitäts- und Landesbibliothek Münster
Entstanden
- 2020
Ähnliche Objekte (12)
The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies
Deubiquitinases in hematological malignancies
Overview of the side-effects of FDA- and/or EMA-approved targeted therapies for the treatment of hematological malignancies
Checkpoint inhibitors in hematological malignancies
Rac GTPases in hematological malignancies
Hematological Malignancies and Arterial Thromboembolism
Mitochondrial transfer in hematological malignancies
XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy
Targeting immune checkpoints in hematological malignancies
Cellular immunotherapy for refractory hematological malignancies
IL-31, itch and hematological malignancies
Role of CD47 in Hematological Malignancies
The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies
Deubiquitinases in hematological malignancies
Overview of the side-effects of FDA- and/or EMA-approved targeted therapies for the treatment of hematological malignancies
Checkpoint inhibitors in hematological malignancies
Rac GTPases in hematological malignancies
Hematological Malignancies and Arterial Thromboembolism
Mitochondrial transfer in hematological malignancies
XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy
Targeting immune checkpoints in hematological malignancies
Cellular immunotherapy for refractory hematological malignancies
IL-31, itch and hematological malignancies
Role of CD47 in Hematological Malignancies
The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies
Deubiquitinases in hematological malignancies
Overview of the side-effects of FDA- and/or EMA-approved targeted therapies for the treatment of hematological malignancies
Checkpoint inhibitors in hematological malignancies
Rac GTPases in hematological malignancies
Hematological Malignancies and Arterial Thromboembolism
Mitochondrial transfer in hematological malignancies
XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy
Targeting immune checkpoints in hematological malignancies
Cellular immunotherapy for refractory hematological malignancies
IL-31, itch and hematological malignancies